All Posts Tagged With: "CELG"

An ‘Immense’ Opportunity in One Small-Cap Biotech

Marc Lichtenfeld at The Smart Profits Report says he’s found an “immense” investment opportunity in a small-cap biotech firm.

There are three entry points in biotech stocks. They are: The first stages of research for a new drug; the initial human trial phases; and immediately before the drug is FDA approved. The later the entry point, the safer the investment.

The stock Marc has his eye on is a late-stage company. It is finishing Phase III trials for a unique cancer treatment drug which, if successful, will corner an entire market.

Great Bargains in Ignored Biotech

There has been a lot of strong recommendations around biotech lately on Contrarian Profits.

Phase 1 Investor editor Rob Fannon recently wrote that biotech was one of the few market sectors to show positive returns as  many other stocks were getting hammered. He sees great values in the sector.

There’s a good reason for this strength. A struggling economy won’t hurt biotech and medical as much as, say, an automaker, retailer, or restaurant chain… And biotech is one of the few industries showing solid sales growth.

What Hedge-Fund Managers are Reading This Morning

Last May, shares of Regeneron Pharmaceuticals (REGN), a billion-dollar biotech, slid 35% in just 30 days. The company had no press releases, no earnings reports, nothing.

Receive These Valuable Investing Strategy Resources to Your Inbox Courtesy of Contrarian Profits

    Subscribe
We respect your privacy.
Choose any of the FREE subscription services below that you'd like to receive, enter your email address, and click 'subscribe'.
Contrarian Profits

The Daily Reckoning



Select Edition:
Penny Sleuth

Money Morning

Investor's Daily Edge

Money Morning UK

Investment U

Whiskey and Gunpowder

Taipan Daily

Offshore A-Letter

Today's Financial News

The Smart Profits Report

Casey Research